In this phase 1 , double-blind trial ( NCT01603264 ) , 105 healthy male volunteers were randomized 1:1:1 to receive a single 6mgkg ( -1 ) intravenous dose of PF-05280014 , trastuzumab-EU , or trastuzumab-US , and evaluated for 70 days .